Science can improve health and wellbeing in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
More than 11,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products.
A Canadian R&D Leader
GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. GSK invested more than $60 million in Canadian research and development (R&D) in 2020.
- In 2020, GSK invested over $ 9.1 million into 32 active clinical trials across Canada involving 1,303 active subjects.
- In 2020, GSK supported 14 Investigator Sponsored Studies with physicians across Canada.
- In 2020, GSK sponsored approximately 18 Canadian research projects focused on health economics and outcomes research to support the scientific understanding of our medicines and vaccines in Canada.
Supporting R&D Innovation in Canada
To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organizations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.
In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies. GSK Canada works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs as the Quebec Consortium for Drug Development (CQDM) to investigate new therapeutic targets as well as disruptive platforms for discovery and development.
Click here to see our current areas of interest.
Sharing our research
As part of our commitment to transparency, we are reporting the results of all our research, where the outcomes are perceived to be positive or negative.